SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, has reached a historic milestone: more than two million patients genomic profiles analyzed on the AI-powered analytics Platform SOPHiA DDM. This achievement solidifies SOPHiA GENETICS as the gold-standard provider of actionable insights for patient care, applying AI capabilities shaped by an unmatch

Celonic Group leverages Merck’s Breez micro-bioreactor technology to optimize bioprocessing efficiency and scalability. This technology integration supports Celonic’s efforts to enhance expertise in monoclonal antibody (mAb) development and manufacturing through advanced Next-Generation Technologies. Celonic’s streamlined production, enabled by Merck’s technology, sets new standards in red

Full study results are expected in June 2025, but early results demonstrate strong potential; 60% of trial patients experienced full or partial lesion clearance.

Volv Global has more than doubled its office space for the fourth year in a row to support a rapidly growing international team. Expansion driven by accelerating demand for its proprietary AI-driven healthcare insights. New space fosters collaboration, innovation, and impact—driving precision in difficult-to-diagnose diseases.

Adoram Therapeutics Secures Pre-Seed Investment to Advance Innovative Cancer Immunotherapy and Inflammation Programs

Reduced monthly HAE attack rate maintained for at least 1.5 years in CHAPTER-1 OLE study; median proportion of days with symptoms in OLE was further reduced to zero days All participants in CHAPTER-1 OLE who had reached week 62 reported improved health-related quality of life Ongoing RAPIDe-2 extension study includes efficacy data from seven upper airway, including laryngeal, attacks; median time